Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound HealingSeptember 23, 2026
Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative TechnologySeptember 16, 2026
Tempo Therapeutics selected into MedTech Innovator’s highly competitive 2025 Accelerator CohortJune 9, 2025
Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 For Tissue Repair in Skin Cancer SurgerySeptember 5, 2024
Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical TrialsMarch 19, 2024
